Explore the Agenda
8:00 am Breakfast & Registration
8:55 am Chair’s Opening Remarks
9:00 am The Great Isotope Debate: Which Therapeutic Radionuclide Will Define the Next 5 Years of TRP Development? Seven Isotope Specialists, Seven Perspectives.
Experience a fast-paced debate, where isotope specialists will each present the strongest case for their radionuclide before joining a moderated discussion comparing clinical evidence, manufacturing readiness, supply considerations and commercial potential. Hear contrasting perspectives, challenge conventional thinking and take part in the discussion as the audience helps determine which isotope will define the next five years of TRP development.
- Comparing the scientific, clinical, manufacturing and commercial advantages of emerging isotopes including Actinium-225, Lead-212, Copper-67, Terbium, Astatine-211 and Lutetium-177
- Evaluating which radionuclides are best positioned to win across therapeutic efficacy, supply scalability, dosimetry flexibility, theranostic integration and global clinical applicability
- Challenging each isotope expert to defend why their radionuclide will become the hottest, most commercially impactful and most clinically transformative isotope over the next five years
10:00 am Morning Break, Networking, & Go to Tracks
Discovery & Preclinical Track
Discovery & Preclinical Track
Strengthening Non-Clinical Preclinical Strategy to Improve Clinical Success
10:55 am Welcome from Seminar Leads
11:00 am The Safety Profile Playbook: Advancing Dosage Optimisation & Safety Assessment Strategies for Therapeutic Radiopharmaceutical Development
Executive Director ,Senior GPSL Team Lead & Group Head for Radiopharmaceuticals safety, Novartis
- Exploring evolving approaches to dosage optimisation during therapeutic radiopharmaceutical development to improve therapeutic index whilst maintaining patient safety
- Assessing how dosimetry, renal safety evaluation and longitudinal toxicity monitoring can be more effectively integrated into clinical development strategy and regulatory decision-making
- Discussing opportunities to modernise safety assessment frameworks for radiopharmaceutical therapies in line with emerging clinical data, novel isotopes and next-generation treatment paradigms
11:30 am From FAP to B7-H3: What Determines Whether a Radiopharmaceutical Target Successfully Translates to the Clinic?
Program Pipeline Manager - Head of Innovation & Translational Development Unit, Belgian Nuclear Research
- Identifying the key biological, translational and clinical characteristics that differentiate high-potential radiopharmaceutical targets from those unlikely to succeed
- Exploring how target expression, tumour microenvironment interactions and biomarker strategies influence development decisions
- Understanding the role of preclinical modelling, radiobiology and imaging in strengthening confidence before clinical translation
12:00 pm Roundtable Discussion: Where Should the Field Place Its Next Bet? Prioritising the Next Generation of Radiopharmaceutical Targets
Key Questions to Be Addressed:
- Should the field continue investing in established targets, or is it time to prioritise first-in-class biology despite the increased risk?
- What level of biological, translational and preclinical evidence is needed before advancing a novel radiopharmaceutical target into IND-enabling studies?
- What lessons can be learned from targets that failed to translate clinically, and how should these shape future target selection and portfolio strategies?
Translational & Clinical Track
Supply Chain & CMC
12:30 pm Lunch Break
Discovery & Preclinical Track
1:30 pm Target Selection Strategy Lab: What Makes a Winning Radiopharmaceutical Target?
Chief Scientific Officer, Molecular Partners
- Evaluating the biological, translational and clinical characteristics that separate promising radiopharmaceutical targets from those unlikely to succeed in development
- Debating how developers should balance target expression, tumour selectivity, internalisation, accessibility and heterogeneity when prioritising targets for investment
- Comparing the opportunities and limitations of established and emerging targets including DLL3, FAP, CAIX and others to determine where the next wave of radiopharmaceutical innovation will emerge
Building Smarter Outsourcing Strategies to Strengthen Clinical Translation
2:30 pm From Discovery to First-in-Human: Navigating the Critical Preclinical Decisions That Determine Translational Success
Chief Operating Officer, Precirix
- Identifying the scientific, operational and regulatory milestones required to successfully advance a radiopharmaceutical from the laboratory into the clinic
- Determining how to generate the right translational data package to de-risk first-in-human studies and strengthen investor confidence
- Understanding the most common challenges encountered when moving from academic innovation to clinical development and how to proactively address them
3:00 pm Follow-Up Mastermind Session: Translational Readiness Challenge
Working in small groups, attendees will assess a hypothetical radiopharmaceutical program preparing for first-in-human studies and determine whether it is truly ready to progress into the clinic
- Identifying the critical scientific, preclinical, CMC, and regulatory evidence still required before IND submission
- Prioritizing the highest-risk translational gaps that could delay clinical entry or reduce investor confidence
- Developing a practical action plan to strengthen the data package and accelerate progression into first-in-human studies
Translational & Clinical Track
Supply Chain & CMC
Designed to accelerate partner selection, these interactive Meet & Match sessions connect radiopharmaceutical developers with leading CROs, dosimetry providers, radiopharmacies and CDMOs.
Discovery & Preclinical Track
3:30 pm Preclinical CRO Meet & Match: Connecting Developers with the Translational Partners Advancing Next-Generation TRPs
- Meeting specialist preclinical CROs supporting radiopharmaceutical discovery, biodistribution, dosimetry, toxicology, imaging and translational model development across emerging TRP platforms
- Exploring how different CRO capabilities, animal models and radiobiology expertise align with specific isotope strategies, targeting modalities and first-in-human development goals
- Benchmarking potential preclinical partners through focused networking discussions designed to accelerate outsourcing decisions, translational planning and early development execution
Translational & Clinical Track
Supply Chain & CMC